诺和诺德2026年底前停止在欧盟销售维格列汀

DoNews
Sep 05

2025年9月5日,欧洲药品管理局(EMA)披露,诺和诺德将在2026年底前停止在欧盟及欧洲经济区销售降糖药维格列汀。维格列汀主要用于治疗2型糖尿病,此次决定可能与药物安全性或市场策略调整有关。目前,相关患者将需在医生指导下更换治疗方案。

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10